DIO Valuation

Is A039840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A039840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A039840 (₩15940) is trading above our estimate of fair value (₩3370.82)

Significantly Below Fair Value: A039840 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039840?

Key metric: As A039840 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A039840. This is calculated by dividing A039840's market cap by their current revenue.
What is A039840's PS Ratio?
PS Ratio2x
Sales₩112.56b
Market Cap₩228.93b

Price to Sales Ratio vs Peers

How does A039840's PS Ratio compare to its peers?

The above table shows the PS ratio for A039840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.1x
A475960 Tomocube
36.3xn/a₩184.9b
A100120 Vieworks
0.9x8.6%₩191.9b
A043150 Value Added Technology
0.7x8.5%₩279.3b
A206640 Boditech Med
2.4x15.9%₩339.3b
2x21.9%₩228.9b

Price-To-Sales vs Peers: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (10.1x).


Price to Sales Ratio vs Industry

How does A039840's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
A008490 Suheung
0.2x6.9%US$96.04m
0.6xn/aUS$42.51m
0.3xn/aUS$23.48m
A043100 AlphanoxLtd
0.4xn/aUS$7.83m
No more companies available in this PS range
A039840 2.0xIndustry Avg. 2.0xNo. of Companies14PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A039840 is expensive based on its Price-To-Sales Ratio (2x) compared to the KR Medical Equipment industry average (2x).


Price to Sales Ratio vs Fair Ratio

What is A039840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio3.9x

Price-To-Sales vs Fair Ratio: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A039840 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩15,940.00
₩21,666.67
+35.9%
10.9%₩25,000.00₩20,000.00n/a3
Dec ’25₩17,000.00
₩21,666.67
+27.5%
10.9%₩25,000.00₩20,000.00n/a3
Nov ’25₩16,290.00
₩20,600.00
+26.5%
4.1%₩21,800.00₩20,000.00n/a3
Oct ’25₩16,350.00
₩20,600.00
+26.0%
4.1%₩21,800.00₩20,000.00n/a3
Sep ’25₩16,200.00
₩23,600.00
+45.7%
16.5%₩29,000.00₩20,000.00n/a3
Aug ’25₩19,360.00
₩29,500.00
+52.4%
1.7%₩30,000.00₩29,000.00n/a2
Jul ’25₩19,050.00
₩32,000.00
+68.0%
11.1%₩37,000.00₩29,000.00n/a3
Jun ’25₩19,380.00
₩32,000.00
+65.1%
11.1%₩37,000.00₩29,000.00n/a3
May ’25₩20,600.00
₩36,750.00
+78.4%
4.0%₩39,000.00₩35,000.00n/a4
Apr ’25₩22,500.00
₩36,750.00
+63.3%
4.0%₩39,000.00₩35,000.00n/a4
Mar ’25₩21,100.00
₩36,750.00
+74.2%
4.0%₩39,000.00₩35,000.00n/a4
Feb ’25₩19,380.00
₩38,200.00
+97.1%
8.3%₩44,000.00₩35,000.00n/a5
Jan ’25₩22,400.00
₩38,200.00
+70.5%
8.3%₩44,000.00₩35,000.00n/a5
Dec ’24₩21,100.00
₩38,200.00
+81.0%
8.3%₩44,000.00₩35,000.00₩17,000.005
Nov ’24₩23,600.00
₩42,600.00
+80.5%
6.7%₩47,000.00₩39,000.00₩16,290.005
Oct ’24₩25,300.00
₩43,600.00
+72.3%
5.1%₩47,000.00₩40,000.00₩16,350.005
Sep ’24₩29,950.00
₩43,600.00
+45.6%
5.1%₩47,000.00₩40,000.00₩16,200.005
Aug ’24₩31,200.00
₩43,600.00
+39.7%
5.1%₩47,000.00₩40,000.00₩19,360.005
Jul ’24₩33,950.00
₩43,333.33
+27.6%
6.6%₩47,000.00₩40,000.00₩19,050.003
Jun ’24₩29,000.00
₩38,250.00
+31.9%
23.9%₩47,000.00₩23,000.00₩19,380.004
May ’24₩29,700.00
₩38,250.00
+28.8%
23.9%₩47,000.00₩23,000.00₩20,600.004
Apr ’24₩24,850.00
₩31,250.00
+25.8%
15.7%₩35,000.00₩23,000.00₩22,500.004
Mar ’24₩24,400.00
₩33,000.00
+35.2%
17.0%₩40,000.00₩23,000.00₩21,100.005
Feb ’24₩21,850.00
₩34,500.00
+57.9%
20.1%₩40,000.00₩23,000.00₩19,380.004
Jan ’24₩19,700.00
₩34,500.00
+75.1%
20.1%₩40,000.00₩23,000.00₩22,400.004
Dec ’23₩19,600.00
₩34,500.00
+76.0%
20.1%₩40,000.00₩23,000.00₩21,100.004

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 09:32
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DIO Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Min-young LeeDaishin Securities Co. Ltd.
Ji-Eun KimDB Financial Investment Co. Ltd.
Jaesong WooHaitong International Research Limited